

TO THE EDITOR:

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy

Fateeha Furqan,¹ Morgan Maring,¹ Aniko Szabo,² Timothy S. Fenske,¹ Mehdi Hamadani,¹ and Nirav N. Shah¹

¹Bone Marrow Transplant & Cellular Therapy Program, Department of Medicine, and ²Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

Despite the exceptional initial response rates with chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), the duration of response (DOR) is short and more than half the patients relapse.^{1,2} Patients who fail to respond or relapse after CAR T-cell therapy have a poor prognosis, especially those who relapse within 30 days.³ Treatment options after CAR T-cell therapy are limited and persistent cytopenias can limit the use of salvage therapy or participation in clinical trials.⁴ In a study by Spiegel et al, 26% of the patients who progressed after CAR T-cell received supportive care whereas 74% received various therapies.⁵ The overall response rate (ORR) in more commonly used therapies was 29%, with only 17% of the patients achieving a complete response (CR) while median progression-free survival (PFS) and overall survival (OS) were 55 days and 180 days, respectively.

Although multiple new agents are available for relapsed LBCL, durable remissions in the post-CAR T-cell therapy setting are uncommon. In the pre-CAR T-cell therapy era, for patients who relapsed after autologous stem cell transplant (auto-HCT), allogeneic transplant (allo-HCT) was a curative intent procedure offered to chemosensitive patients. This procedure has fallen out of favor in light of novel immunotherapies, targeted agents, and cell therapies (Figure 1A). However, in patients with lymphoma failing CAR T-cell therapy, allo-HCT may benefit selected patients.⁶⁻⁹ We report below our experience using polatuzumab as a salvage agent and a bridge to allo-HCT, in patients with non-Hodgkin lymphoma (NHL) who failed CD19-based CAR T-cell therapy, as an approach to achieve long term remission.

We performed a retrospective, single-center analysis of patients with relapsed or refractory B-cell NHL who relapsed after CD19 based CAR T-cell therapy and subsequently received polatuzumab based salvage chemotherapy. This was approved by the Medical College of Wisconsin Institutional Review Board and informed consent was waived. Data were obtained from electronic medical record. Descriptive statistics were used to detail baseline characteristics. The Kaplan-Meier methodology was used to calculate OS and PFS graphs. Statistical analyses were performed using STATA v13.1 and SAS v9.4.

We identified 17 patients with B-cell NHL who relapsed after CAR T-cell therapy and received polatuzumab based treatment for the first time. The ORR was 71% (2, partial response [PR]; 10, CR). Two patients received only polatuzumab and rituximab whereas bendamustine or lenalidomide was added to 12 and 3 patients, respectively.

Out of these 17 patients, 9 patients underwent allo-HCT (Table 1). The median age of these patients was 66 years (range, 41-72); 8 had diffuse LBCL whereas 1 had grade 3 follicular lymphoma. For these 9 patients, the day-28 ORR to initial CAR T-cell therapy on positron emission tomography (PET) was 89% (CR = 7; PR = 1) whereas the median DOR was 5 months (range, 1-26). For relapse after CAR T-cell therapy, the median lines of therapy were 1 (range, 1-4). Median cycles of polatuzumab were 3 (range, 2-4), and 6 out of 9 patients received polatuzumab as their first salvage treatment. After

Submitted 26 September 2022; accepted 17 November 2022; prepublished online on *Blood Advances* First Edition 23 November 2022. <https://doi.org/10.1182/bloodadvances.2022009025>.

Data are available on request from the corresponding author, Nirav N Shah (nishah@mcw.edu).

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.




Figure 1. Decreasing trends of allo-HCT over the last decade (A) and duration of response of patients after CAR T (red) and after polatuzumab followed by allo-HCT (blue). (A) Decreasing trend of Utilization of Allogeneic Transplant in DLBCL provided by the Center for International Blood and Marrow Transplant Research (CIBMTR), (B) Swimmers Plot reporting duration of response after CAR T-cell therapy and after allo-HCT by subject.

polatuzumab and before allo-HCT, 8 patients were in CR, whereas 1 had a PR. All patients then received reduced intensity or non-myeloablative conditioning (RIC/NMA) followed by peripheral blood mobilized stem cells, 5 of which were matched as related, 3 were matched unrelated, and 1 was a haploidentical transplant. All

patients received calcineurin inhibitor-based prophylaxis for GVHD while the 1 patient with haploidentical allo-HCT also received post-transplant cyclophosphamide. The median times to neutrophil and platelet recovery were 16 days (range, 4-18) and 13 days (range, 8-29), respectively. Five patients had acute GVHD, 1 of which was

Table 1. Baseline characteristics of patients receiving allo-HCT after polatuzumab bridging (n = 9)

Patient No.	Histologic diagnosis, COO	Age at Allo-HCT/ Sex	CAR T-cell Therapy Administered	No. lines of therapy prior to CAR	Response to CAR	DOR to CAR	No. of therapies after CAR relapse	LDH prior to Pola (U/L)	No. of Pola cycles	Disease status before allo-HCT/ Best response to Pola	Days to neutrophil/ platelet recovery	Acute GVHD grade	Chronic GVHD/ severity	Relapse after Allo-HCT	Survival/ Disease status at last follow-up	DOR to allo-HCT (mo)	Follow-up (mo)
1	DLBCL, GCB	46/F	LV20.19 CAR	3	CR	5.1	1	323	2	CR	4/19	1	0	N	Alive/CR	19.5	19.5
2	Transformed DLBCL, non-GCB	66/F	Axi-cel	3	CR	2.8	4	244	3	CR	17/14	0	0	Y	Alive/CR	12	24.7
3	DLBCL, GCB	70/M	LV20.19 CAR	3	PR	2.3	3	306	4	CR	14/29	1	0	N	Alive/CR	32.4	32.4
4	DLBCL, GCB (triple hit)	62/M	LV20.19 CAR	2	PD	0	1	283	3	CR	18/12	0	0	N	Alive/CR	12	12
5	FL, grade 3A	68/M	LV20.19 CAR	3	CR	4.0	1	277	4	PR	17/15	1	0	N	Alive/CR	9.7	9.7
6	DLBCL, non-GCB	41/M	LV20.19 CAR	3	CR	26.2	2	286	3	CR	16/12	4	0	N	Alive/PR	3.5	9.0
7	DLBCL, GCB	65/F	Axi-cel	2	CR	6.5	1	192	3	CR	16/8	1	Moderate	Y	Alive/CR	29.2	29.2
8	DLBCL, GCB	72/M	LV20.19 CAR	3	CR	5.9	1	213	3	CR	15/11	0	0	N	Alive/CR	9.6	9.6
9	DLBCL, non-GCB	66/F	Axi-cel	3	CR	6.5	1	1067	CR	16/10	0	0	N	Alive/CR	4.7	4.7	9

Axi-cel, Axicabtagene ciloleucel; COO, cell of origin; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B; GVHD, graft-versus-host-disease; LV20.19, lentiviral anti-CD20/anti-CD19 CAR; Pola, polatuzumab; PD, progressive disease.

grade 4. Only 1 patient had moderate chronic GVHD. At day 90 after allo-HCT, the ORR was 89% on PET (CR = 8; PR = 0). Seven of the 9 patients remain in CR to date with a median follow-up of 12 months (range, 4.7-32.4). Similarly, 7 of the 9 patients have experienced remission inversion with a longer remission after allo-HCT than that of CAR T-cell therapy (Figure 1B). Median PFS was not reached (supplemental Figure 1), and all patients remain alive (supplemental Figure 2) and are currently without evidence of disease (including the 2 patients who relapsed).

In this study, we report durable remissions with allo-HCT in selected patients who achieved a deep response with polatuzumab based salvage chemotherapy after CAR T-cell therapy. Seven out of 9 patients experienced a longer remission after allo-HCT than with CAR T-cell therapy, and 5 patients are now >1 year in remission, demonstrating allo-HCT is feasible and facilitates sustained remissions. The median PFS was not reached, and all patients remain alive to date which is likely related to our usage of RIC regimens for B-cell lymphoma, limiting nonrelapse mortality (NRM). Outcomes of polatuzumab after CAR T-cell therapy relapse were recently reported by Gouni et al.¹⁰ Among 54 patients who received polatuzumab, the ORR was 44%. Although our outcomes are superior, we acknowledge that most patients in this report were responding to CAR T-cell therapy who later relapsed and not patients who were primarily refractory to CAR-directed therapy. More importantly, in the study by Gouni et al, the median DOR to polatuzumab was only 11 weeks, suggesting that responses to polatuzumab are short lived without an appropriate consolidation such as allo-HCT as used in our study. To facilitate timely allo-HCT, we did not administer 6 cycles of polatuzumab as reported by Sehn et al.¹¹ The median number of polatuzumab doses was 3. Additional cycles were forgone to facilitate allo-HCT consolidation, demonstrating that early allo-HCT intensifies and prolongs responses because polatuzumab alone does not lead to durable response in this patient population.⁴

Previous studies have reported on allo-HCT outcomes after CAR T-cell therapy failure with various induction regimens.^{12,13} In a recent study, Zurko et al reported 1-year PFS, OS, and NRM of 40%, 51%, and 27%, respectively, in 65 patients with LBCL after a median follow-up of 14 months.¹² The higher NRM reported in the study by Zurko et al may be because of variable conditioning including myeloablative (MAC) regimens in 25% of patients. As prior studies have demonstrated unclear benefit and a higher NRM with MAC in lymphoma patients, our approach of RIC regimens limited the NRM, which is 0% to date.^{14,15} Shadman et al also reported outcomes of allo-HCT in 13 patients with NHL and chronic lymphocytic leukemia who relapsed after CAR T-cell therapy.¹³ The 1-year OS and NRM were 59% and 33%, respectively. Again, the higher NRM may be attributed to the higher use of MAC that was administered in 38% of patients. Gerhardt et al reported on 2 patients with aggressive lymphomas who received salvage therapy with 3 cycles of polatuzumab, bendamustine, and rituximab followed by MAC and allo-HCT, who were disease-free at last follow-up.¹⁶

In conclusion, albeit small, our study suggests that polatuzumab is an effective salvage therapy that can lead to deep responses facilitating a curative intent allo-HCT in patients who have failed CAR T-cell therapy. This approach led to durable remissions, with most patients (78%) achieving a longer disease-free period after allo-HCT than that after CAR T-cell therapy. Given the limited

response duration to salvage therapy in general for patients who progress after CD19 based CAR T-cell therapy, our data emphasize the role of early consolidation with allo-HCT after clinical response. With the expected adaptation of polatuzumab in the frontline, its effectiveness in the post-CAR T-cell therapy setting will evolve. However, we speculate with other emerging treatments, which if able to induce a response, that consolidation with allo-HCT may similarly facilitate a durable remission for post-CAR T-cell therapy relapses.

Contribution: F.F. and N.N.S. conceptualized and designed the study, and prepared the first draft; F.F., M.M., and N.N.S. collected and assembled the data; F.F., A.S., and N.N.S. analyzed the data; and all authors interpreted the data, helped revise the manuscript, and approved the final version of the manuscript.

Conflict-of-interest disclosure: T.S.F. consults and/or is in communication with Adaptive Biotechnologies, AstraZeneca, Beigene, Kite (Gilead), MorphoSys, Pharmacyclics (AbbVie), Sanofi, SeaGen, Servier Pharmaceuticals, and TG Therapeutics. M.H. consults with Incyte Corporation, ADC Therapeutics, Pharmacyclics, Omeros, Genmab, Morphosys, Kadmon, Kite, Novartis, AbbVie, Legend, Gamida Cell, and SeaGen, and is in the speaker's bureau of Sanofi Genzyme, AstraZeneca, BeiGene, and ADC Therapeutics. N.N.S. is on the advisory board and/or consults with Kite Pharma, BMS, TG therapeutics, Miltenyi Biotec, Lilly, Epizyme, Legend, Incyte, Novartis, and Umoja, and has research funding and honoraria from Miltenyi Biotec. The remaining authors declare no competing financial interests.

ORCID profiles: F.F., 0000-0001-7262-4953; M.M., 0000-0002-9728-2221; A.S., 0000-0002-8129-0614; M.H., 0000-0001-5372-510X; N.N.S., 0000-0002-4336-1071.

Correspondence: Nirav N. Shah, Bone Marrow Transplant & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, 200 West Wisconsin Ave, Milwaukee, WI 53226; email: nishah@mcw.edu.

References

1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large b-cell lymphoma. *N Engl J Med*. 2017; 377(26):2531-2544.
2. Chong EA, Ruella M, Schuster SJ. Lymphoma program investigators at the university of p. five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. *N Engl J Med*. 2021;384(7):673-674.
3. Chow VA, Gopal AK, Maloney DG, et al. Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. *Am J Hematol*. 2019;94(8):E209-E213.
4. Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. *Haematologica*. 2021;106(10):2667-2672.
5. Spiegel JY, Dahiya S, Jain MD, et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. *Blood*. 2021;137(13):1832-1835.
6. Imber BS, Sadelain M, DeSelm C, et al. Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. *Br J Haematol*. 2020;190(1):45-51.

7. Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2021; 22(6):790-800.
8. Thieblemont C, Chevret S, Allain V, et al. Lenalidomide enhance CAR T-cells response in patients with refractory/relapsed large B cell lymphoma experiencing progression after infusion. *Blood*. 2020; 136(Supplement 1):16-17.
9. Graf SA, Cassaday RD, Morris K, et al. Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma. *Clin Lymphoma Myeloma Leuk*. 2021;21(3):176-181.
10. Gouni S, Rosenthal AC, Crombie JL, et al. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. *Blood Adv*. 2022;6(9): 2757-2762.
11. Sehn LH, Hertzberg M, Opat S, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. *Blood Adv*. 2022;6(2): 533-543.
12. Zurko J, Ramdial J, Shadman M, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma, *Haematologica*. Published online 14 July 2022. <https://doi.org/10.3324/haematol.2022.281242>
13. Shadman M, Gauthier J, Hay KA, et al. Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. *Blood Adv*. 2019;3(20):3062-3069.
14. Epperla N, Ahn KW, Khanal M, et al. Impact of reduced-intensity conditioning regimens on outcomes in diffuse large B cell lymphoma undergoing allogeneic transplantation. *Transplant Cell Ther*. 2021; 27(1):58-66.
15. Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. *JAMA Oncol*. 2020;6(7):1011-1018.
16. Gerhardt K, Jentzsch M, Georgi T, et al. Salvage therapy with polatuzumab vedotin, bendamustine, and rituximab prior to allogeneic hematopoietic transplantation in patients with aggressive lymphomas relapsing after therapy with chimeric antigen receptor T-cells-report on two cases. *Front Oncol*. 2021;11:737645.